BioSpace News Archive

JDRF, the leading global funder of type 1 diabetes research, proudly announces the appointment of Dr. Shareef Elnahal to the JDRF Research Committee.

Pressure BioSciences, Inc. today announced that the Company will host a teleconference to discuss its Second Quarter 2021 financial results and provide a business update.

Diabetes Research Connection, a 501 that connects early-career scientists and donors to fund research projects aimed at prevention, cure, and better care for those with T1 Diabetes, is accepting letters of intent through August 31 for research grants ranging from $25,000 - $50,000.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Manufacturing Officer, Tushar Misra, Ph.D.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units, and inducement restricted stock units to new employees.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, is pleased to highlight positive results from an independent analysis of standard surgical risk patients undergoing carotid endarterectomy and transcarotid artery revascularization for atherosclerotic carotid disease.

Omnicell, Inc. today announced its latest enhancements to the Company’s industry-leading portfolio of medication management solutions.

Conformis, Inc. (NASDAQ:CFMS) today announced the first procedure with the new Conformis Identity Imprint knee replacement system.

Captura announced that it has signed an agreement with GEM Global Yield LLC SCS (“GEM”), the Luxembourg-based private alternative investment group providing Captura with a Share Subscription Facility of up to $50 Million over a 36-month term following a public listing of Captura’s common stock.